University Hospitals of Licester
Welcome,         Profile    Billing    Logout  
 5 Trials 
9 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Khunti, Kamlesh
MELS, NCT04256720: The Multi-Ethnic Lifestyle Study

Recruiting
N/A
9500
Europe
No intervention
University of Leicester
Diabetes Mellitus, Chronic Kidney Diseases, Cardiovascular Diseases, Obstructive Sleep Apnea, Respiratory Disease, Cancer, Stroke, Chronic Pain, Mental Health Issue (E.G., Depression, Psychosis, Personality Disorder, Substance Abuse), Healthy
11/23
05/24
Davies, Melanie J
STRIVE, NCT03036800: Saxenda in Obesity Services ( Study)

Completed
4
392
Europe
Saxenda, Liraglutide 3mg, Specialist Obesity Management Services
University of Leicester, Novo Nordisk A/S
Obesity, Weight Loss, Diabetes Mellitus
02/21
02/22
SURPASS-EARLY, NCT05433584: A Study of Tirzepatide Compared With Intensified Conventional Care in Adult Participants With Type 2 Diabetes

Active, not recruiting
4
780
Europe, Canada, US, RoW
Tirzepatide, LY3298176, Antihyperglycemic medication
Eli Lilly and Company
Type 2 Diabetes
10/25
11/27
TRIUMPH-4, NCT05931367: A Study of Retatrutide (LY3437943) Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee

Active, not recruiting
3
405
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Obesity, Overweight, Osteo Arthritis Knee
02/26
03/26
TRIUMPH-1, NCT05929066: A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight

Active, not recruiting
3
2300
Europe, Canada, US, RoW
Retatrutide, LY3437943, Placebo
Eli Lilly and Company
Obesity, Overweight, Osteoarthritis, Knee, Obstructive Sleep Apnea
04/26
05/26
SURMOUNT-MMO, NCT05556512: A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity

Active, not recruiting
3
15374
Europe, Canada, Japan, US, RoW
Tirzepatide, LY3298176, Placebo
Eli Lilly and Company
Obesity, Overweight
10/27
10/27
VISTA, NCT06553599: Effects of AZD5004 in Adults Who Are Living With Obesity or Overweight With at Least 1 Weight-related Comorbidity

Not yet recruiting
2
285
Europe, Canada, US, RoW
AZD5004, Active IMP, Placebo
AstraZeneca
Obesity or Overweight
08/25
12/25
VISTA, NCT06579092: Effects of AZD5004 in Adults Who Are Living With Obesity or Overweight With at Least 1 Weight-related Comorbidity

Recruiting
2
304
Europe, Canada, Japan, US, RoW
AZD5004, Active IMP, Placebo
AstraZeneca
Obesity or Overweight
12/25
12/25
NCT06471634: A Study Looking to Improve Sleep and Reduce Sedentary Behaviour in Those Living With Type 2 Diabetes Mellitus

Not yet recruiting
N/A
44
Europe
CBTi, Control - usual care, Sedentary behaviour reduction
University of Leicester, University Hospitals, Leicester
Diabetes Mellitus, Type 2, Insomnia, Sedentary Behavior
07/26
07/26

Download Options